Moderna (NASDAQ:MRNA) +15.1% after-hours on news it shipped the first batch of its mRNA-1273 vaccine against the novel coronavirus to U.S. government researchers to be used in a planned phase 1 study in the U.S.
Moderna says it sent vaccine vials from its Norwood, Mass., manufacturing plant to the National Institute of Allergy and Infectious Diseases in Bethesda, Md.